Randomized clinical trials are and will continue to be the key vehicle for evaluation of new and existing cancer therapies. This revolutionary era of advances in the biological sciences is leading to the discovery of novel biomarkers and complex genetic and genomic information that may be highly associated with various clinical outcomes, offering the tantalizing opportunity to exploit this information to both improve the precision of the analyses of trials and to develop models of longitudinal disease progression that may reveal important insights. A recurrent challenge is that missing data and subject drop-out are commonplace, presenting complications for analyses of these trials. Through a series of aims addressing these issues, this project proposes research that will have a significant impact on the quality and strength of inferences possible from current cancer clinical trials. That it is possible to improve efficiency of primary analyses of clinical trials by exploiting prognostic baseline auxiliary information is well known;however, such analyses are controversial because of the temptation to choose the analysis that leads to the most dramatic treatment effect. In the first aim, new methods for such "covariate adjustment" will be studied that circumvent this issue and can improve over existing approaches. In the second aim, these methods will be extended so that they may be used in the common case where outcomes are missing due to drop-out. Efficient methods for longitudinal analysis of measures such as quality of life and biomarkers in the presence of drop-out will also be developed. Understanding the relationship between such longitudinal measures and clinical outcomes such as time to recurrence or survival time is of key importance.
The third aim focuses on development of methods for assessing the correctness of so-called joint statistical models used for this purpose and for assessing the influence of particular observations on the fit ofthe model, where the data used to develop the model may be missing. Finally, taking appropriate account of missing data sometimes requires unverifiable assumptions about why the data are missing, which are incorporated in models that thus cannot be checked based on the data.
The fourth aim i s devoted to development of a new statistical framework for assessing how sensitive conclusions are to the modeling assumptions made.
Randomized clinical trials in cancer research are the most important mechanism for the evaluation of new and existing therapies. Statistical methods will be developed that will improve the precision of the analyses of these trials and provide tools for drawing valid conclusions when some of the data intended to be collected are missing, e.g., if some subjects drop out ofthe trial, offering cancer researchers an expanded set of tools that will greatly improve the quality and strength of analyses of current cancer clinical trials.
|Wang, Zhi; Maity, Arnab; Luo, Yiwen et al. (2015) Complete effect-profile assessment in association studies with multiple genetic and multiple environmental factors. Genet Epidemiol 39:122-33|
|Geng, Yuan; Zhang, Hao Helen; Lu, Wenbin (2015) On optimal treatment regimes selection for mean survival time. Stat Med 34:1169-84|
|Liu, Yulun; Chen, Yong; Chu, Haitao (2015) A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard. Biometrics 71:538-47|
|Chen, Qingxia; Zeng, Donglin; Ibrahim, Joseph G et al. (2015) Quantifying the average of the time-varying hazard ratio via a class of transformations. Lifetime Data Anal 21:259-79|
|Viele, Kert; Berry, Scott; Neuenschwander, Beat et al. (2014) Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat 13:41-54|
|Chen, Ming-Hui; Ibrahim, Joseph G; Zeng, Donglin et al. (2014) Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome. Biometrics 70:1003-13|
|Wang, Xin; Zhang, Daowen; Tzeng, Jung-Ying (2014) Pathway-guided identification of gene-gene interactions. Ann Hum Genet 78:478-91|
|Zhang, Jing; Carlin, Bradley P; Neaton, James D et al. (2014) Network meta-analysis of randomized clinical trials: reporting the proper summaries. Clin Trials 11:246-62|
|Lin, Ja-An; Zhu, Hongtu; Mihye, Ahn et al. (2014) Functional-mixed effects models for candidate genetic mapping in imaging genetic studies. Genet Epidemiol 38:680-91|
|Molenberghs, Geert; Kenward, Michael G; Aerts, Marc et al. (2014) On random sample size, ignorability, ancillarity, completeness, separability, and degeneracy: sequential trials, random sample sizes, and missing data. Stat Methods Med Res 23:11-41|
Showing the most recent 10 out of 133 publications